KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Shares Outstanding: 2013-2025

Historic Shares Outstanding for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $77.1 million.

  • Xenon Pharmaceuticals' Shares Outstanding rose 1.75% to $77.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.1 million, marking a year-over-year increase of 1.75%. This contributed to the annual value of $76.4 million for FY2024, which is 1.39% up from last year.
  • Xenon Pharmaceuticals' Shares Outstanding amounted to $77.1 million in Q3 2025, which was up 0.23% from $76.9 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Shares Outstanding ranged from a high of $77.1 million in Q3 2025 and a low of $41.0 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding was $75.7 million (2024), whereas its average is $72.8 million.
  • Data for Xenon Pharmaceuticals' Shares Outstanding shows a peak YoY soared of 51.38% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Shares Outstanding stood at $51.6 million in 2021, then rose by 21.21% to $62.6 million in 2022, then grew by 20.42% to $75.4 million in 2023, then increased by 1.39% to $76.4 million in 2024, then rose by 1.75% to $77.1 million in 2025.
  • Its Shares Outstanding was $77.1 million in Q3 2025, compared to $76.9 million in Q2 2025 and $76.6 million in Q1 2025.